Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection

BACKGROUND: Middle East respiratory syndrome coronavirus (MERS-CoV), a new coronavirus that emerged in 2012, causes severe and fatal acute respiratory illness in man. Its high mortality (roughly 38%) has raised public fear worldwide, calling for the development of effective and safe therapeutics to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lancet
Glavni autori: Jiang, Shibo, Tao, Xinrong, Xia, Shuai, Garron, Tania, Yu, Fei, Du, Lanying, Lu, Lu, Tseng, Chien-Te K
Format: Artigo
Jezik:Inglês
Izdano: Elsevier Ltd. 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7159274/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00625-X
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items